All terms in HP

Label Id Description
Hyperthreoninuria HP_0003296 [An increased concentration of threonine in the urine.]
Increased RIPA HP_0040241 [Increased platelet agglutination in response to low-dose ristocetin]
obsolete Impaired FSH and LH secretion HP_0003295
Muscle hemorrhage HP_0040242 [Bleeding occurring within a muscle]
Spina bifida occulta HP_0003298 [The closed form of spina bifida with incomplete closure of a vertebral body with intact overlying skin.]
Prolonged euglobulin clot lysis time HP_0040243 [Abnormally increased length of time required for an in vitro clot to dissolve in the absence of the normal plasmin inhibitors. This test is a clinical assay used to measure fibrinolysis. The euglobulin fraction of plasma is precipitated and used to form clot by addition of thrombin; after clot forms the rate of clot breakdown (fibrinolysis) can be monitored.]
Hyperlysinuria HP_0003297 [An increased concentration of lysine in the urine.]
Prolonged Russell's viper venom time HP_0040244 [Increased time to coagulation in the Russell's viper venom assay]
Decreased serum leptin HP_0003292 [A decreased concentration of leptin in the blood.]
Abnormal circulating leptin concentration HP_0004361 [An abnormal concentration of leptin in the blood.]
Increased ratio of VWF propeptide to VWF antigen HP_0040240 [An increased VWF propeptide to VWF antigen indicates that deficiency of VWF is not due to impaired synthesis but due to rapid clearance. The VWF propeptide is measured by ELISA.]
Reduced plasminogen activator inhibitor 1 antigen HP_0040249 [Reduced level of plasminogen activator inhibitor 1 antigen.]
Abnormal circulating plasminogen activator inhibitor 1 activity HP_0430126 [The activity or concentration of plasminogen activator inhibitor-1 in the blood circulation is outside of the limits of the normal range.]
Reduced alpha-2-antiplasmin activity HP_0040245 [Reduced activity of alpha-2-antiplasmin. This protein inactivates the protease plasmin that drives fibrinolysis.]
Reduced antithrombin antigen HP_0040246 [Reduced antithrombin antigen. A reduced level of antithrombin may lead to an increased risk of thrombus formation.]
Reduced euglobulin clot lysis time HP_0040247 [Abnormally decreased length of time required for an in vitro clot to dissolve in the absence of the normal plasmin inhibitors. This test is a clinical assay used to measure fibrinolysis. The euglobulin fraction of plasma is precipitated and used to form clot by addition of thrombin; after clot forms the rate of clot breakdown (fibrinolysis) can be monitored.]
Reduced plasminogen activator inhibitor 1 activity HP_0040248 [Reduced activity of plasminogen activator inhibitor 1. This protein down-regulates fibrinolysis in the circulation by inhibiting the two major plasminogen activators: tissue-plasminogen activator and urokinase-plasminogen activator.]
Abnormal response to short acting pulmonary vasodilator HP_0030893 [Pulmonary vasodilator testing is performed during right-heart catheterization and involves a short-acting vasoactive agent such as adenosine, epoprostenol, or inhaled nitric oxide. The current definition of a normal (positive) response is a drop in mean pulmonary artery pressure of at least 10 mm Hg (or 20 percent) to below 40 mm Hg.]
Insufficient response to short acting pulmonary vasodilator HP_0030894 [No fall in mean pulmonary arterial pressure (mPAP) falls by at least 10 mmHg to an absolute value less than 40 mmHg without a degradation in cardiac output (CO) in response to a short-acting vasoactive agent such as adenosine, epoprostenol, or inhaled nitric oxide.]
Hyperintensity of cerebral white matter on MRI HP_0030890 [A brighter than expected signal on magnetic resonance imaging emanating from the cerebral white matter.]